Currently, the FDA approved the neoadjuvant approach with nivolumab, whereas the EMA restricted the approval of neoadjuvant nivolumab to those tumors with PD-L1 ≥1% NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.